fashion -WSS

fashion

author：knowledge 2025-10-02 20:49:03 - browse：5

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s like to see the technology approved for human use, and more.

The need-to-know this morning:
• Bayer said it prematurely stopped a Phase 3 study in stroke prevention after independent monitors concluded its experimental blood-thinning medicine, called asundexian, showed inferior efficacy compared to a standard treatment. The asundexian study setback is a significant blow to Bayer’s effort to revamp its drug-development pipeline, analysts said.
• Carmot Therapeutics filed paperwork Friday for an initial public offering of undisclosed size. The Berkeley, Calif.-based company is developing drugs that target GLP-1 and GIP to treat diabetes and obesity, similar to Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound.
• Bristol Myers Squibb and 2Seventy Bio said the FDA will not complete an on-time review of its application seeking to expand the use of Abecma, their CAR-T therapy for multiple myeloma. Instead, the FDA will convene an advisory panel meeting — date to be determined — to examine survival data from an Abecma clinical trial.
• The U.K. and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as the country tries to keep a lid on its medicines spending while simultaneously building up its life sciences industry. STAT’s Andrew Joseph has more here.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Statins may not be needed by millions of people, study suggests

Wikipedia

WSS

As a primary care physician, here's how I hope to partner with AI

Addressing health care workers' trauma can help fight burnout

5 takeaways from STAT's examination of Zynex Medical

Cheap, fast test for Zika and dengue could cost just $1

Fentanyl is making it harder to start addiction treatment

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

knowledge

fashion

focus

Dobbs anniversary: the lost opportunity of abortion as health care

Cue Health, Covid

Apple is now the first public company to be valued at $3 trillion

Health care court cases: Humana, Sutter, Novant

In age of alternative facts, a scholarly course on calling out crap

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

23andMe had bad news about my health. I wish a person had delivered it

Reports of telehealth's death have been greatly exaggerated

New air purifier tech could be key to improving indoor air quality

ASCO eve: Let’s set the table for this year's meeting

entertainment

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

UnitedHealth argues against case alleging wrongful AI care denials

Biogen joins immunology wave with $1.15 billion acquisition of HI

ASCO eve: Let’s set the table for this year's meeting

The system is set up to fail children with medical complexity

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Wikipedia

focus

Wikipedia

knowledge